

Provider Bulletin May 2022

Medical Policies and Clinical Utilization Management Guidelines update

The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.

Please share this notice with other members of your practice and office staff.

To view a guideline, visit https://www.anthem.com/provider/policies/clinical-guidelines/search.

Notes/updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

- *CG-LAB-20 Thyroid Testing:
 - Outlines the Medically Necessary and Not Medically Necessary criteria for thyroid testing.
- *CG-LAB-21 Serum Iron Testing:
 - Outlines the Medically Necessary and Not Medically Necessary criteria for serum iron testing.
- *LAB.00043 Immune Biomarker Tests for Cancer:
 - Oncologic immune biomarker tests are considered *Investigational and Not Medically Necessary* for all indications.
- *LAB.00044 Saliva-Based Testing to Determine Drug-Metabolizer Status:
 - Saliva-based testing to determine drug-metabolizer status is considered *Investigational* and *Not Medically Necessary* for all indications.
- *LAB.00045 Selected Tests for the Evaluation and Management of Infertility:
 - The following tests or procedures are considered *Investigational and Not Medically Necessary* for diagnosing or managing infertility:
 - Endometrial receptivity analysis
 - Sperm-capacitation test
 - Sperm deoxyribonucleic acid (DNA) fragmentation test
 - Sperm penetration assay
 - Uterine natural killer (uNK) cells test
- *LAB.00046 Testing for Biochemical Markers for Alzheimer's Disease:
 - Measurements of biochemical markers (including but not limited to tau protein, AB-42, neural thread protein) is considered *Investigational and Not Medically Necessary* as a diagnostic technique for individuals with symptoms suggestive of Alzheimer's disease.
 - Measurements of biochemical markers as a screening technique in asymptomatic individuals with or without a family history of Alzheimer's disease is considered Investigational and Not Medically Necessary.
 - Moved content related to biomarker testing for Alzheimer's disease from GENE.00003 Biochemical Markers for the Diagnosis and Screening of Alzheimer's Disease to this document.

- *RAD.00067 Quantitative Ultrasound for Tissue Characterization:
 - Quantitative ultrasound for tissue characterization is considered *Investigational and Not Medically Necessary* for all indications.
- *SURG.00154 Microsurgical Procedures for the Prevention or Treatment of Lymphedema:
 - o Revised *Position Statement* to include the prevention of lymphedema.
- *SURG.00160 Implanted Port Delivery Systems to Treat Ocular Disease:
 - The use of a port delivery system to treat ocular disease is considered *Investigational* and *Not Medically Necessary* for all indications.
- *TRANS.00038 Thymus Tissue Transplantation:
 - Outlines the Medically Necessary and Investigational and Not Medically Necessary criteria for allogeneic processed thymus tissue.

Medical Policies

On February 17, 2022, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem. These guidelines take effect June 17, 2022.

Publish	Medical Policy	Medical Policy title	New or
date	number		revised
04/13/2022	*LAB.00043	Immune Biomarker Tests for Cancer	New
04/13/2022	*LAB.00044	Saliva-based Testing to Determine Drug-Metabolizer Status	New
04/13/2022	*LAB.00045	Selected Tests for the Evaluation and Management of Infertility	New
04/13/2022	*LAB.00046	Testing for Biochemical Markers for Alzheimer's Disease	New
04/13/2022	*RAD.00067	Quantitative Ultrasound for Tissue Characterization	New
04/13/2022	*SURG.00160	Implanted Port Delivery Systems to Treat Ocular Disease	New
03/25/2022	*TRANS.00038	Thymus Tissue Transplantation	New
04/13/2022	GENE.00052	Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling	Revised
04/1/2022	SURG.00011	Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting	Revised
02/24/2022	SURG.00036	Fetal Surgery for Prenatally Diagnosed Malformations	Revised
04/13/2022	SURG.00096	Surgical and Ablative Treatments for Chronic Headaches	Revised
04/13/2022	*SURG.00154	Microsurgical Procedures for the Prevention or Treatment of Lymphedema	Revised

Clinical UM Guidelines

On February 17, 2022, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem Blue Cross and Blue Shield. These guidelines adopted by the medical operations committee for BadgerCare Plus members on March 24, 2022. These guidelines take effect June 17, 2022.

Publish date	Clinical UM Guideline number	Clinical UM Guideline title	New or revised
04/13/2022	*CG-LAB-20	Thyroid Testing	New
04/13/2022	*CG-LAB-21	Serum Iron Testing	New
04/13/2022	CG-GENE-14	Gene Mutation Testing for Cancer Susceptibility and Management	Revised
04/13/2022	CG-MED-73	Hyperbaric Oxygen Therapy (Systemic/Topical)	Revised
04/13/2022	CG-SURG-36	Adenoidectomy	Revised
02/24/2022	CG-SURG-86	Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection	Revised



Email is the quickest and most direct way to receive important information from Anthem Blue Cross and Blue Shield.



To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (https://bit.ly/3zszbJF).